

Chair: Zinaida Perić

GvHD subcom: Olaf Penack

AI subcom: Alberto Mussetti

Early comps and regimen-related toxicities subcom: Ivan Moiseev

Secretary: Ivan Moiseev

Survivorship subcom: Hélène Schoemans

CAR-T comps subcom: Charlotte Graham

Publications in 2023

Penack O. et al. **Severe cytopenia after CD19 CAR T-cell therapy.** J Immunother Cancer. 2023 Apr;11(4):e006406. doi: 10.1136/jitc-2022-006406.

Ruutu T. et al. **Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients.** Bone Marrow Transplant. 2023 Aug 12. doi: 10.1038/s41409-023-02077-2. Epub ahead of print.

Gjærde LK. et al. **Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation.** Bone Marrow Transplant. 2023 Aug 23. doi: 10.1038/s41409-023-02067-4. Online ahead of print.

Penack O. et al. **Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma.** Front. Immunol. 2023 Sep 27:14:1252811. doi: 10.3389/fimmu.2023.1252811. eCollection 2023.

Mussetti A. et al. **Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era.** Bone Marrow Transplant. 2023 Nov 25. doi: 10.1038/s41409-023-02147-5. Online ahead of print.

Gjærde LK. et al. **The impact of pre-transplantation diabetes and obesity on acute graft-versus-host disease, relapse and death after allogeneic hematopoietic cell transplantation.** Bone Marrow Transplant. 2023 Dec 7. doi: 10.1038/s41409-023-02154-6.

Penack O. et al. **ECP versus ruxolitinib in steroid-refractory acute GVHD.** Front Immunol. 2023 Dec 11:14:1283034. doi: 10.3389/fimmu.2023.1283034. eCollection 2023.

Presentations at EBMT 2024

Oral Presentations

- **Gagelmann N.** Daratumumab for PRCA after HCT.
- **Güven M.** Impact of blood group disparities on allo outcomes.
- **Moiseev I.** Outcomes in $\leq 8/10$ HLA match MUD.
- **Penack O.** NRM after second allo.

Poster Presentations

- **Brijs J.** Immune checkpoint inhibitors post allo HCT.
- **Piekarska A.** ATG in MSD allo-HCT.
- **Montoro J.** Lung transplantation post allo HCT.
- **Snarski E.** Non-cryopreserved stem cells for auto (with IDWP).

Manuscripts in Writing/Finalisation Phase

- **Bilinski J.** Fecal microbiota transplant for GvHD.
- **Damm F. & Schetelig J.** CHIP studies.
- **Durakovic N.** Graft rejection in haploSCT survey.
- **Orti G.** GvHD after CAR-T therapy.
- **Penack O.** CAR-T cell outcomes in patients with comorbidities.
- **Penack O.** PTCy vs. ATG in MUD allo.
- **Penack O.** PTCy vs. ATG in MMUD allo.
- **Penack O.** CAR-T complications management survey.

- **Perić Z.** Steroid refractory acute GvHD survey.
- **Pulanic D.** Chronic GvHD over time.
- **Salas MQ.** Outcomes of PTCy in elderly AML/MDS.
- **Salooja N.** Pregnancy outcomes among SCT survivors.
- **Schoemans H.** Patient engagement survey.
- **Schultze-Florey C.** Impact of BMI on CAR-T cell therapy.
- **Tomaszewska A.** Complications of CTX-based haploSCTs.
- **Turki A.** Machine learning and GvHD.

Active Studies

- **Mekinian A.** Autoimmune complications of alloHCT.
- **Moiseev I.** Severity and response in TA-TMA.
- **Novak P.** Secondary HLH post alloHCT.
- **Rudakova T.** Poor graft function in alloSCT (boost).

- **Salooja N. & Horgan C.** Management of passage from paediatric to adult centres (transition survey).
- **Schultze-Florey C.** SGLT2 inhibitors survey.

Upcoming Studies

- **Avenoso D.** Late complications of VOD.
- **Desnica L.** GvHD and relapse.
- **Dreta B.** Eosinophilia after CAR-T cell therapy.

- **Dachy G.** TMA after CAR-T cell therapy.
- **Stoelzel F.** Pseudo-progression after CAR-T cell therapy.